We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

38 hedge funds and large institutions have $2.42M invested in SAB Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $2.32M → $2.42M (+$96.9K)

0.18% more ownership

Funds ownership: 0.77% → 0.95% (+0.18%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

5% less funds holding

Funds holding: 40 → 38 (-2)

Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
9
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
V
Veritable
Delaware
+$423K
2
WAM
Warberg Asset Management
Illinois
+$339K
3
HighTower Advisors
HighTower Advisors
Illinois
+$69.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$63.1K
5
SOS
Silver Oak Securities
Tennessee
+$47.5K

Top Sellers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
-$105K
2
SCM
Shaolin Capital Management
Florida
-$35.1K
3
Millennium Management
Millennium Management
New York
-$27K
4
Jane Street
Jane Street
New York
-$17K
5
BlackRock
BlackRock
New York
-$16.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
FPB
1
First PREMIER Bank
South Dakota
$476K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$414K +$530 +58 +0.1%
V
3
Veritable
Delaware
$299K +$423K +46,296 +1,063%
WAM
4
Warberg Asset Management
Illinois
$219K +$339K +37,037 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$177K -$14.7K -1,613 -5%
SCM
6
Shaolin Capital Management
Florida
$140K -$35.1K -3,838 -14%
IFAM
7
Institutional & Family Asset Management
Colorado
$88.4K – – –
MC
8
Meteora Capital
Florida
$79.4K -$105K -11,501 -46%
Citadel Advisors
9
Citadel Advisors
Florida
$64.4K +$63.1K +6,906 +172%
BlackRock
10
BlackRock
New York
$63.8K -$16.1K -1,757 -14%
BCM
11
Bridgeway Capital Management
Texas
$49.6K – – –
State Street
12
State Street
Massachusetts
$47.9K – – –
HighTower Advisors
13
HighTower Advisors
Illinois
$44K +$69.4K +7,597 New
Mariner
14
Mariner
Kansas
$41K – – –
SOS
15
Silver Oak Securities
Tennessee
$31K +$47.5K +5,194 New
Creative Planning
16
Creative Planning
Kansas
$28.6K +$914 +100 +2%
Northern Trust
17
Northern Trust
Illinois
$26.2K – – –
LP
18
LGL Partners
Pennsylvania
$13.6K – – –
BCM
19
Brookstone Capital Management
Illinois
$13.3K +$4.83K +529 +32%
Osaic Holdings
20
Osaic Holdings
Arizona
$11.3K +$15.4K +1,689 +764%
AWM
21
AE Wealth Management
Kansas
$11K – – –
Morgan Stanley
22
Morgan Stanley
New York
$10.2K -$7.18K -786 -31%
Charles Schwab
23
Charles Schwab
California
$9.58K – – –
ECM
24
Elgethun Capital Management
South Dakota
$9.17K +$1.37K +150 +11%
NFG
25
Nadler Financial Group
Illinois
$8.11K +$12.6K +1,375 New
1
2

SABS Hedge Fund Activity: Q4 2022 in Review

38 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2022, worth a combined $2.42M — up 4.2% from $2.32M a quarter earlier.

Fund positioning in SABS was balanced in Q4 2022: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 9 trimmed.

The largest buyer was Veritable, adding an estimated $423K. The largest seller was Meteora Capital, cutting an estimated $105K.

  • 38 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2022, down from 40 in Q3 2022.
  • Funds reported $2.42M of SAB Biotherapeutics stock for Q4 2022, up 4.2% quarter-over-quarter.
  • 8 funds opened new SAB Biotherapeutics positions in Q4 2022 and 8 closed out, a net change of 0 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2022 was Veritable, an estimated $423K added.
  • The largest SAB Biotherapeutics seller in Q4 2022 was Meteora Capital, an estimated $105K sold.

Based on aggregated 13F filings for Q4 2022.